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power of the COX models considerably and should be interpreted
as underlining our ﬁndings.
In order to perform the Kaplan Meier analysis it was necessary
to dicotomise the groups into those with and without fatigue. The
rationale for this was described fully in the original description of
the cohort [2]. The COX model allowed us to explore the absolute
level of FIS score. Both analyses conﬁrmed the relationship
between fatigue and mortality and, therefore, we cannot under-
stand how Yousaf and Yeoman can now suggest ‘‘how the pres-
ence (or otherwise) of fatigue affects mortality in an
independent model is not certain’’.
The authors are correct, in the COX model UDCA therapy was
not independently predictive of improved mortality and on the
basis of this they refute our conclusions regarding UDCA. We
believe inclusion of categorical data into a COX model is a blunt
instrument and we would direct Yousuf and Yeoman to the other
analyses in the results section which clearly show that the effect
that UDCA response has upon mortality is clearly independent of
the effect that fatigue status has. This is an important message for
clinicians managing patients with PBC in that it conﬁrms that
non-fatigued patients who are UDCA responders are at very low
risk. This is one of the key messages from the paper.
In summary, we question what further data the authors con-
sider required to conﬁrm to them that it has now gone from
beyond the ‘‘possible that fatigue is independently associated with
increased mortality in PBC’’ if they believe that our well charac-
terised comprehensively collected geographically deﬁned cohort
does not ‘‘prove that this is the case in respect of the presence
or otherwise of fatigue’’. Furthermore we would suggest that
we clearly show, albeit in a small cohort, that response to UDCA
therapy has an effect on mortality.
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Open access under CCSLC40A1-R178G mutation and ferroportin diseaseTo the Editor:
In their excellent systematic meta-analysis on the ferroportin
disease, recently published in the Journal of Hepatology, Mayr
et al. present in detail all the described SLC40A1 gene alterations
and their relationship with disease phenotype [1]. The prevalence
of these alterations in the general population is also presented,
indicating that a few of them are polymorphisms with an
unknown, as yet, biological signiﬁcance.
Amongst these alterations, the authors include the mutation
SLC40A1-R178G, described by us in a Greek family with
ferroportin disease [2], despite the fact that they refer regarding
this mutation (Table 3), obviously by mistake, to another
publication. To this end, it is interesting to present information
derived from the 2-year follow-up of the affected members of
this family, as well as the data missing from the literature popu-
lation that we have acquired in the mean time, indicating that the
SLC40A1-R178G mutation is not a polymorphism. Instead, they
support our position that it represents a novel mutation resulting
in classical ferroportin disease with a mild, and rather variable,
phenotype.
In our previous publication, the SLC40A1-R178G mutation was
found to be responsible for a classical ferroportin disease pheno-
type in a 25-year-old female [2], who remains in excellent condi-
tion being subjected to periodical venesections every threeJournal of Hepatology 2
 BY-NC-ND license.months. Examining the family tree, we detected the same muta-
tion in the proband’s 53-year-old mother, presenting with slight
hyperferritinemia and liver hemosiderosis of moderate degree.
During the follow-up, her hyperﬁrretinemia worsened, necessi-
tating therapeutic venesections. The SLC40A1-R178G mutation
was also detected in the proband’s 87-year-old grandfather
who displayed low transferrin saturation, but not hyperferritin-
emia. Because of his old age, this patient, the oldest one in the lit-
erature diagnosed with ferroportin disease, was not submitted to
further evaluation regarding the possible coexistence of iron deﬁ-
ciency. Two years after the diagnosis, he remains alive without
needing venesections.
Following this atypical presentation of ferroportin disease and
considering that the SLC40A1-R178G mutation had not been
observed in large comprehensive population studies [3–5], we
questioned whether it was a functional polymorphism prevalent
in the Greek population.
To this end, we analyzed 253 bone marrow donors (male/
female: 123/130, mean age: 34.7 years, range: 21–60) from Cen-
tral Greece area. All subjects provided written informed consent,
while the study was conducted in accordance with the principles
of Helsinki declaration and was approved by the Institutional
Review Board of the University Hospital of Larissa, Greece. Geno-
mic DNA was extracted from peripheral blood using the QIAamp011 vol. 55 j 729–733
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Fig. 1. SLC40A1-R178G mutation identiﬁed by PCR–RFLP. The forward and
reverse primers used were 50-CTTACCTGCCTCTTTC-30 and 50-CATTGTGTTCAGTT-
TACC-30 , respectively. The PCR conditions were: 2 min at 94 C followed by 33
cycles (94 C for 30 s, 54 C for 30 s, 72 C for 30 s), and 5 min at 72 C after the
last cycle. A 293 bp fragment was ampliﬁed by PCR and subjected to HpyAV
digestion (New England Biolabs, UK) at 37 C for 8 h. The wild-type allele contains
two HpyAV sites resulting in 139, 112, and 42 bp fragments, while the presence of
a 178G allele results in an additional 181 bp fragment, due to the abrogation of a
digestion site. M: 200 bp ladder molecular weight marker (Invitrogen, UK); lane
1: blank, negative PCR control; lane 2: PCR product and lane 3: digestion products
of a sample heterozygous for the SLC40A1-R178G mutation; lane 4: PCR product
and lane 5: digestion products of a wild-type sample. The 42 bp fragments were
not visible on agarose gels.
JOURNAL OF HEPATOLOGYDNA Blood Mini kit (Qiagen, UK). The detection of the R178G
mutation was performed after ampliﬁcation of the exon 6 of
SLC40A1 gene by PCR and subsequent restriction-digestion (RFLP,
Restriction Fragment Length Polymorphism) analysis (Fig. 1). The
protocol was designed based on the fact that the mutation results
in the creation of a DNA sequence that is not recognized by the
restriction enzyme HpyAV (New England Biolabs, UK). All PCR
and digestion procedures were carried out in the PCR-engine
apparatus PTC-200, MJ-Research (Watertown-Massachusetts),
while the PCR and digestion products were analyzed in 2.5%
TBE agarose gels (Fig. 1). For the conﬁrmation of PCR–RFLP
results, randomly chosen PCR products were puriﬁed by Qiagen
PCR Puriﬁcation System (Qiagen, UK) and directed sequenced
using an ABI Prism 310 Genetic Analyzer (Applied Biosystems,
Foster City, CA) and a Big Dye pTerminator DNA sequencing kit
(Applied Biosystems).
No individual carrying the SLC40A1-R178G mutation was
found, supporting, in parallel with the ﬁndings of the above men-
tioned family, its causative relation with ferroportin disease.
Finally, we would like to emphasize that the speciﬁc PCR–
RFLP protocol utilized in this study can also be applied for theReply to: SLC40A1-R178G muta
To the Editor:
Clearly, the observation that R178G was not found in 253
ethnically matched bone marrow donors, supports Dr. Speletas’
and his colleagues’ notion that R178G is a rare sequence variant.
The concept that R178G is a disease causing mutation is chal-
Journal of Hepatology 20detection of another mutation found in the 178R amino acid, pro-
viding a rapid and reliable approach for the analysis of speciﬁc
alterations of the SLC40A1 gene.
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lenged by the apparently incomplete penetrance of this mutation
in the family reported. Additional clinical information provided in
the letter above further supports the notion that the index case
and her mother are affected by an iron storage disease that can
be regarded as a genuine ferroportin disease. However, absence
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